Kieron Dunleavy
- Pathology and Forensic Medicine top 0.1%
- Lymphoma Diagnosis and Treatment 120
- Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research 51
- Oncology top 0.5%
- Viral-associated cancers and disorders 32
- CAR-T cell therapy research 29
- Neurology top 0.5%
- CNS Lymphoma Diagnosis and Treatment 39
- Hematology top 2%
-
- Lung Cancer Treatments and Mutations 11
-
- Ubiquitin and proteasome pathways 8
-
- Cancer Genomics and Diagnostics 7
- Co-authors
- Wyndham H. WilsonElaine S. JaffeStefania PittalugaSeth M. SteinbergLouis M. StaudtNicole GrantRichard F. LittleJohn E. Janik
- Journals
- New England Journal of Medicine (2 papers)Nature Medicine (1 paper)Journal of Clinical Oncology (25 papers)
- Partner nations
- United StatesGermanySpain
In The Last Decade
Kieron Dunleavy
140 papers receiving 5.5k citations
Hit Papers
Peers
Comparison fields: 5 of 107
- Pathology and Forensic Medicine 3.6k
- Genetics 1.6k
- Oncology 2.7k
- Neurology 1.3k
- Hematology 484
Countries citing papers authored by Kieron Dunleavy
This map shows the geographic impact of Kieron Dunleavy's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kieron Dunleavy with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kieron Dunleavy more than expected).
Fields of papers citing papers by Kieron Dunleavy
This network shows the impact of papers produced by Kieron Dunleavy. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kieron Dunleavy. The network helps show where Kieron Dunleavy may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Kieron Dunleavy, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 0 | |
| 2 | 2024 | 7 | |
| 3 | 2024 | 36 | |
| 4 | 2023 | 7 | |
| 5 | 2023 | 0 | |
| 6 | 2022 | 13 | |
| 7 | 2022 | 61 | |
| 8 | 2019 | 0 | |
| 9 | 2016 | 111 | |
| 10 | 2016 | 68 | |
| 11 | 2013 | 5 | |
| 12 | 2011 | 82 | |
| 13 | 2010 | 123 | |
| 14 | 2010 | 80 | |
| 15 | Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activitybreakdown → | 2010 | 663 |
| 16 | 2010 | 27 | |
| 17 | 2009 | 371 | |
| 18 | 2008 | 217 | |
| 19 | Rituximab, chemotherapy, and HIV-associated lymphoma | 2006 | 1 |
| 20 | 2005 | 85 |
About Kieron Dunleavy
Kieron Dunleavy is a scholar working on Pathology and Forensic Medicine, Genetics and Neurology, having authored 149 papers that have together received 5.6k indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (120 papers), Chronic Lymphocytic Leukemia Research (51 papers), CNS Lymphoma Diagnosis and Treatment (39 papers), Viral-associated cancers and disorders (32 papers), CAR-T cell therapy research (29 papers), Lung Cancer Treatments and Mutations (11 papers), Ubiquitin and proteasome pathways (8 papers) and Cancer Genomics and Diagnostics (7 papers). The work is most often cited by research in Pathology and Forensic Medicine (3.6k citations), Genetics (1.6k citations) and Oncology (2.7k citations). Kieron Dunleavy has collaborated with scholars based in United States, Germany and Spain. Frequent co-authors include Wyndham H. Wilson, Elaine S. Jaffe, Stefania Pittaluga, Seth M. Steinberg, Louis M. Staudt, Nicole Grant, Richard F. Little, John E. Janik, Margaret Shovlin and Clíona Grant. Their work appears in journals such as New England Journal of Medicine, Nature Medicine and Journal of Clinical Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.